Dynavax Technologies | Resultat Før Skatt



Pre Tax Profit Endring Dato
AbbVie USD 4.81B 1.54B 2024-12
Adma Biologics USD 36.75M 898K 2024-09
Amgen USD 3.38B 111M 2024-12
AstraZeneca USD 1.67B 162M 2024-12
Biogen USD 572.2M 118.5M 2024-12
BioMarin Pharmaceutical USD 169.64M 35.2M 2024-12
Bristol-Myers Squibb USD 4.26B 226M 2024-12
Dynavax Technologies USD 7.63M 12.19M 2024-12
Gilead Sciences USD 2.96B 112M 2024-12
Glaxosmithkline USD 1.66B 1.78B 2024-12
Merck USD 5.22B 114M 2024-12
Neurocrine Biosciences USD 162.6M 27.7M 2024-12
Novartis USD 4.66B 269M 2024-12
Pfizer USD 4.44B 2.36B 2024-12
Regeneron Pharmaceuticals USD 958.1M 534.9M 2024-12
Roche Holding CHF 1.78B 2.33B 2024-12
Sarepta Therapeutics USD 171.74M 137.74M 2024-12
TG Therapeutics USD 25.45M 21.18M 2024-12
Vertex Pharmaceuticals USD 1.32B 109.7M 2024-12



Dynavax Technologies Resultat Før Skatt - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.